The News Review:

- Vicor Technologies CE David Fater Discusses Company’s Diagnostics …
- MCRU consolidates two of its performance sites
- Sangart Inc. Announces Key Executive Appointments and Company …
- Breast cancer gene linked to disease spread identified
- Michael J. Fox Foundation Awards $2.7 Million to Four Industry …

Vicor Technologies CE David Fater Discusses Company’s Diagnostics …
CNNMoney.com 
The PD2i CA (Cardiac Analyzer) in a multi-sitemulti-year trial (the VITAL Trial) being conducted by the Harvard ClinicalResearch Institute identifies patients at risk of suffering sudden cardiacdeath. Vicor anticipates additional applications employing the PD2i to enableearly detection and risk stratification for a variety of other disordersand diseases. Additional information is available at.

MCRU consolidates two of its performance sites
U-M Health System News MI 
- Two Michigan Clinical Research Unit performance sites have moved their facilities to the Cardiovascular Center. The Med Inn and University Hospital units have been consolidated into newly designed space which will provide enhanced support for clinical research.

Sangart Inc. Announces Key Executive Appointments and Company …
PR Newswire (press release) NY 
Thesetrials provide a platform from which to conduct the pivotal clinical studiesthat will be necessary to establish the clinical benefit of treating patientswith Hemospan. The appointment of key executives and the decision to reduceour workforce which was difficult but necessary will enable us to focus ourresources on these upcoming clinical trials. As part of the restructuring Sangart announced appointments for four newleadership positions: — Howard Levy MD PhD Chief Scientific fficer — Dr. Levy will assume overall responsibility for preclinical clinical research and research and development for Hemospan. A critical care and pulmonary physician Dr. Levy brings more than 20 years of experience both serving as a principal investigator at research institutions as well as leading clinical study development teams for pharmaceutical companies. Prior to Sangart he was responsible for clinical research of the hemostasis platform at Novo Nordisk Inc.

Breast cancer gene linked to disease spread identified
Thaindian.com Thailand 
According to co-author Michael Reiss director of the Breast Cancer Research Program at The Cancer Institute of New Jersey the discovery is important for several other reasons “Not only has a new metastasis gene been identified but this also is one of a few such genes for which the exact mode of action has been elucidated. That gives us a real shot at developing a drug that will inhibit metastasis” said Reiss also a professor of medicine molecular genetics and microbiology at UMDNJ-Robert Wood Johnson Medical School. The discovery is based on three years of work using an approach that combines the emerging science of integrative genomics with the classical methods of clinical research and laboratory experiments. The study appears in the Jan. 6 edition of Cancer Cell.
Related from Fathernickthomas: Vermont called healthiest state Louisiana last

Michael J. Fox Foundation Awards $2.7 Million to Four Industry …
PR Newswire (press release) NY 
7 Million to Four Industry Teams for Pre-Clinical Parkinson’s Disease Research. Fox Foundation awarded a total of about $2. 7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson’s disease. The funding was awarded under the Foundation’s Therapeutics Development Initiative. This program first launched in 2006 supports and bolsters industry-focused efforts on Parkinson’s research.